Thrombosis Canada Statement on AstraZeneca Vaccine and Blood Clots

Thrombosis Canada guidance is that current evidence does not support a direct link between the vaccine and development of blood clots

TORONTO–(BUSINESS WIRE)–There have been recent reports from Europe that the SARS-CoV-2 (COVID-19) vaccine made by AstraZeneca, which was recently approved for use in Canada, may be associated with thrombotic complications (blood clots).

It is the view of Thrombosis Canada that, based on the available evidence, there is no link between receiving this vaccine and the development of blood clots. In general, vaccines of any type are not associated with the development of blood clots.

Thrombosis is a common medical problem, especially in older people. It is therefore likely that some people who receive a vaccine will, at some point, in the future develop a blood clot for reasons that are not related to the vaccine.

Thrombosis Canada strongly recommends the administration of the COVID-19 vaccines, including in people who have had a previous blood clot, in people with a family member who has had a blood clot, and in people who are receiving a blood thinning treatment (Previous Statement Link).

Disclaimer:

Please note that the recommendations contained herein must be viewed as general guidelines based on current knowledge. Their application must be adapted to individual patients. Thrombosis Canada assumes no responsibility or liability arising from any error or omission or from the use of any information contained herein. You must not rely on the information in this document as an alternative to medical advice from your doctor or other professional healthcare provider.

@ThrombosisCan (www.ThrombosisCanada.ca)

Thrombosis Canada comprises a membership that includes the most eminent and internationally recognized thrombosis experts globally. Members have made many significant contributions to the body of knowledge in vascular medicine and disseminated that knowledge through hundreds of peer-reviewed publications, as well leading the development of international clinical practice guidelines.

Contacts

FOR MORE INFORMATION AND INTERVIEWS WITH DOCTORS, CALL:
David Airdrie

Executive Director

Thrombosis Canada

647-528-8586

[email protected]